1. Home
  2. LOAN vs ANVS Comparison

LOAN vs ANVS Comparison

Compare LOAN & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

HOLD

Current Price

$4.56

Market Cap

50.4M

Sector

Real Estate

ML Signal

HOLD

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$1.91

Market Cap

46.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOAN
ANVS
Founded
1989
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.4M
46.5M
IPO Year
1999
2019

Fundamental Metrics

Financial Performance
Metric
LOAN
ANVS
Price
$4.56
$1.91
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
31.3K
1.2M
Earning Date
04-16-2026
05-12-2026
Dividend Yield
9.48%
N/A
EPS Growth
N/A
39.39
EPS
0.11
N/A
Revenue
$8,666,307.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$42.18
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.13
$1.36
52 Week High
$5.85
$5.50

Technical Indicators

Market Signals
Indicator
LOAN
ANVS
Relative Strength Index (RSI) 55.34 42.47
Support Level $4.33 $1.56
Resistance Level $4.90 $2.67
Average True Range (ATR) 0.17 0.20
MACD 0.01 -0.00
Stochastic Oscillator 43.75 29.23

Price Performance

Historical Comparison
LOAN
ANVS

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About ANVS Annovis Bio Inc.

Annovis Bio Inc is a late-stage clinical drug platform company addressing neurodegeneration, including Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is developing its product candidate, buntanetap, a synthetically produced, orally administered, brain-penetrant small molecule designed to treat AD, PD, and potentially other chronic neurodegenerative diseases by inhibiting the synthesis of neurotoxic proteins and TDP43, which contribute to neurodegeneration and reduced axonal transport. Its pipeline includes buntanetap for chronic neurodegeneration, including AD, PD, and PDD, as well as in certain combination therapies, ANVS405 for acute neurodegeneration, and ANVS301 for AD.

Share on Social Networks: